Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 54 (1), 11-29

Overview of Monoclonal Antibodies in Cancer Therapy: Present and Promise

Affiliations
Review

Overview of Monoclonal Antibodies in Cancer Therapy: Present and Promise

M Stern et al. Crit Rev Oncol Hematol.

Abstract

After 30 years of development, therapy with monoclonal antibodies has started to realize its promise. Clinical use is most widespread in the field of oncology, where half of the agents approved for routine clinical use are employed and a large number of molecules are currently undergoing clinical trials. In the past 2 years alone, three new compounds-the radiolabeled antibody (131)I-tositumomab and two antibodies targeting growth factor receptors (bevacizumab and cetuximab)-have received FDA approval for indications in oncology. This review summarizes the development of this exciting treatment modality over the last three decades, examines the outcome of treatment with these new antibodies and others available for routine clinical use (i.e. rituximab, trastuzumab, alemtuzumab, gemtuzumab ozogamicin, (90)Y-ibritumomab tiuxetan) in standard indications and in experimental settings, and gives a brief outlook on possible future developments.

Similar articles

  • Anticancer Antibodies
    JS Ross et al. Am J Clin Pathol 119 (4), 472-85. PMID 12710120. - Review
    The recent clinical and commercial success of anticancer antibodies such as rituximab and trastuzumab has created great interest in antibody-based therapeutics for hemato …
  • Antibody-based Therapeutics in Oncology
    J Ross et al. Expert Rev Anticancer Ther 3 (1), 107-21. PMID 12597355. - Review
    The recent clinical and commercial success of anticancer antibodies, such as rituximab (Rituxan) and trastuzumab (Herceptin) has created great interest in antibody-based …
  • Monoclonal and Bispecific Antibodies as Novel Therapeutics
    EP Booy et al. Arch Immunol Ther Exp (Warsz) 54 (2), 85-101. PMID 16648969. - Review
    Gene amplification, over-expression, and mutation of growth factors, or the receptors themselves, causes increased signaling through receptor kinases, which has been impl …
  • Monoclonal Antibodies in the Treatment of Cancer, Part 1
    RJ Cersosimo. Am J Health Syst Pharm 60 (15), 1531-48. PMID 12951753. - Review
    Monoclonal antibodies used in the treatment of cancer are discussed. Monoclonal antibodies are a new class of agents targeted at specific receptors on cancer cells. In ad …
  • Newer Monoclonal Antibodies for Hematological Malignancies
    J Castillo et al. Exp Hematol 36 (7), 755-68. PMID 18565392. - Review
    Since the approval of rituximab in 1997, monoclonal antibodies have come to play an important role in the therapy of hematological malignancies. Rituximab, gemtuzumab ozo …
See all similar articles

Cited by 52 PubMed Central articles

See all "Cited by" articles

LinkOut - more resources

Feedback